Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy

Journal of Dermatological Treatment

Volumn 17, Issue 1, 2006, Pages 9-17

  Gordon, Kenneth B ^a,f   Gottlieb, Alice B ^b   Leonardi, Craig L ^c   Elewski, Boni E ^d   Wang, Andrea ^e   Jahreis, Angelika ^e   Zitnik, Ralph ^e  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e AMGEN INC   (United States)

^f Division of Dermatology   (United States)

Author keywords

Clinical trial; Cytokines; TNFR Fc fusion protein

Indexed keywords

ETANERCEPT; HYBRID PROTEIN; PLACEBO;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ANXIETY; ARTICLE; CELLULITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; GASTROENTERITIS; HEADACHE; HEART INFARCTION; HUMAN; HYPERTENSION; INFECTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; OSTEOMYELITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIDE EFFECT; SINUSITIS; TREATMENT RESPONSE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ADULT; BIOLOGICAL RESPONSE MODIFIERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETREATMENT; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 32644479353     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630500472838     Document Type: Article

References (20)

1. Mihatsch MJ, Wolff K. Consensus conference on cyclosporin A for psoriasis February 1992. Br J Dermatol. 1992;126:621-3.
2. Ho VC, Griffiths CE, Berth-Jones J, Papp KA, Vanaclocha F, Dauden E, et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol. 2001;44:643-51.
3. Stern RS, Laird N, Melski J, Parrish JA, Fitzpatrick TB, Bleich HL. Cutaneous squamous-cell carcinoma in patients treated with PUVA. N Engl J Med. 1984;310:1156-61.
4. Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol. 1988;19:145-56.
5. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-22.
6. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627-32.
7. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385-90.
8. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264-72.
9. Krueger GG, Elewski BE, Papp KA, Wang A, Zitnik R, Jahreis A. Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial. J Am Acad Dermatol (in press).
10. Gordon KB, Feldman SR, Koo JYM, Menter A, Rolstad T, Krueger G. Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol. 2005;141:82-4.
11. Moreland L, Baumgartner S, Schiff M, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337:141-7.
12. Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol. 1999;41:51-9.
13. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004-13.
14. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2002;47:821-33.
15. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253-9.
16. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999;130:478-86.
17. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46:1443-50.
18. Lovell D, Giannini E, Reiff A, Cawkwell GD, Silverman ED, Norton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000;342:763-9.
19. Davis D, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48:3230-6.
20. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304-12.